Mannose-modified hyaluronic acid nanocapsules for the targeting of tumor-associated macrophages.

Tumor-associated macrophages (TAMs), a class of immune cells that play a key role in tumor immunosuppression, are recognized as important targets to improve cancer prognosis and treatment. Consequently, the engineering of drug delivery nanocarriers that can reach TAMs has acquired special relevance. This work describes the development and biological evaluation of a panel of hyaluronic acid (HA) nanocapsules (NCs), with different compositions and prepared by different techniques, designed to target macrophages. The results showed that plain HA NCs did not significantly influence the polarization of M0 and M2-like macrophages towards an M1-like pro-inflammatory phenotype; however, the chemical functionalization of HA with mannose (HA-Man) led to a significant increase of NCs uptake by M2 macrophages in vitro and to an improved biodistribution in a MN/MNCA1 fibrosarcoma mouse model with high infiltration of TAMs. These functionalized HA-Man NCs showed a higher accumulation in the tumor compared to non-modified HA NCs. Finally, the pre-administration of the liposomal liver occupying agent Nanoprimer™ further increased the accumulation of the HA-Man NCs in the tumor. This work highlights the promise shown by the HA-Man NCs to target TAMs and thus provides new options for the development of nanomedicine and immunotherapy-based cancer treatments.

A multifunctional drug nanocarrier for efficient anticancer therapy.

So far, the success of anticancer nanomedicines has been moderate due to their lack of adequate targeting properties and/or to their difficulties for penetrating tumors. Here we report a multifunctional drug nanocarrier consisting of hyaluronic acid nanocapsules conjugated with the tumor homing peptide tLyp1, which exhibits both, dual targeting properties (to the tumor and to the lymphatics), and enhanced tumor penetration. Data from a 3D co-culture in vitro model showed the capacity of these nanocapsules to interact with the NRP1 receptors over-expressed in cancer cells. The targeting capacity of the nanocapsules was evidenced in orthotopic lung cancer-bearing mice, using docetaxel as a standard drug. The results showed a dramatic accumulation of docetaxel in the tumor (37-fold the one achieved with Taxotere®). This biodistribution profile correlated with the high efficacy shown in terms of tumor growth regression and drastic reduction of metastasis in the lymphatics. When efficacy was validated in a pancreatic patient-derived tumor, the nanocapsule's activity was comparable to that of a dose ten times higher of Abraxane®. Multi-functionality was found to be the key to the success of this new therapy.

Assessment of the permeability and toxicity of polymeric nanocapsules using the zebrafish model.

AIM: To assess the capacity of a new drug delivery nanocapsule (NC) with a double shell of hyaluronic acid and protamine to overcome biological barriers using the zebrafish model. MATERIALS & METHODS: NCs were prepared by the solvent displacement method, tagged with fluorescent makers and physicochemically characterized. Toxicity was evaluated according to the Fish Embryo Acute Toxicity test, and permeability was tested by exposing zebrafish, with and without chorion, to the fluorescent NCs. RESULTS: Toxicity of NCs was very low as compared with that of a control nanoemulsion. Double-shell NCs were able to cross chorion and skin. CONCLUSION: Beyond the potential value of hyaluronic acid:protamine NCs for overcoming epithelial barriers, this works highlights the utility of zebrafish for fast screening of nanocarriers.

Polyaminoacid nanocapsules for drug delivery to the lymphatic system: Effect of the particle size.

Previous work by our group showed the possibility to reduce the toxicity of docetaxel upon its encapsulation in polyaminoacid nanocapsules with a size of 200nm. The objective of this study was to elucidate whether a reduction in the nanocapsules size might facilitate their access to the lymphatic system. To do so, we analyzed the effect of several formulation parameters on the characteristics of polyglutamic acid, PEGylated polyglutamic acid and polyasparagine nanocapsules. From these experiments, we could identify the best conditions to produce nanocapsules with a small size (close to 100nm) and adequate capacity to encapsulate and sustain the release of the antitumor drug docetaxel. Moreover, the results of the stability study made evident the critical role of the polyaminoacid shell on the colloidal stability of the nanocapsules in biologically relevant media. Finally, we studied the influence of the particle size (100nm vs. 200nm) on the biodistribution of PGA-PEG nanocapsules following subcutaneous injection. The results showed that the 100 nm-size nanocapsules accumulate faster in the lymph nodes, than those with a size of 200nm. In summary, these data suggest the potential of 100nm-size polyaminoacid nanocapsules as lymphatic drug delivery carriers.

On-line ionic imprinted polymer selective solid-phase extraction of nickel and lead from seawater and their determination by inductively coupled plasma-optical emission spectrometry.

Nickel(II) and lead(II) ionic imprinted 8-hydroxyquinoline polymers were synthesized by a precipitation polymerization technique and were used as selective solid phase extraction supports for the determination of nickel and lead in seawater by flow injection solid phase extraction on-line inductively coupled plasma-optical emission spectrometry. An optimum loading flow rate of 2.25 mL min(-1) for 2 min and an elution flow rate of 2.25 mL min(-1) for 1 min gave an enrichment factor of 15 for nickel. However, a low dynamic capacity and/or rate for adsorption and desorption was found for lead ionic imprinted polymer and a flow rate of 3.00 mL min(-1) for 4-min loading and a flow rate of 2.25 mL min(-1) for 1-min elution gave a enrichment factor of 5. The limit of detection was 0.33 microg L(-1) for nickel and 1.88 microg L(-1) for lead, with a precision (n = 11) of 8% (2.37 microg Ni L(-1)) for nickel and 11% (8.38 microg Pb L(-1)) for lead. Accuracy was also assessed by analyzing SLEW-3 (estuarine water) and TM-24 (lake water) certified reference materials, and the values determined were in good agreement with the certified concentrations.